Heart Failure Society of America Holds Annual Meeting
A roundup of news from the Heart Failure Society of America’s annual meeting.
Month: September 2009
Seaside Therapeutics Secures $30M to Fight Autism
Seaside Therapeutics has secured $30 million in funding from a private, unnamed family investment firm committed to finding treatments for autism and Fragile X syndrome.
Xenoport Reports Positive Data for Chronic Pain Drug
Most people wouldn’t think that a case of chicken pox could cause chronic pain, but many people across the U.S. feel the effects of this common childhood disease years after the red spots have disappeared.
First Swine Flu Vaccines Approved
The U.S. government has approved swine flu vaccines from four pharmaceutical companies, Reuters reports.
[Company Profile] Urovalve
Men with acute or chronic urinary retention find that the condition limits their normal activities, causes embarrassment, and poses serious health risks. Urovalve of Newark, NJ, seeks to replace catheterization with an updated treatment that returns bladder control to the patient.
OneMedPlace Interviews Richard T. Schumacher, CEO of Pressure Biosciences
Pressure Biosciences CEO Rick Schumacher discusses the company’s proprietary technology and the high-profile clients that are using it.
FDA Approves Vermillion’s Ovarian Cancer Test
The U.S. Food and Drug Administration has approved a blood test to detect ovarian cancer and help physicians decide what kind of surgery should be done and by whom.
Syneron and Candela to Merge
Syneron Medical will purchase aesthetic laser pioneer Candela Corporation for $65 million, creating a global leader in the medical aesthetic device market.
Opexa Shares Soar on Multiple Sclerosis Trial Data
Opexa Therapeutics announced that 83 percent of clinical trial patients taking its therapeutic vaccine Tovaxin remained relapse-free for a year.